Summary.-The effect has been studied of adding either misonidazole (MISO) or the radioprotective drug, WR 2721, to cyclophosphamide (CY) treatment of mice bearing either the RIF-1 or KHT sarcomas. In RIF-1, the growth delay due to CY was increased by the addition of 1 mg/g of MISO. At doses below 75 mg/kg of CY, the effect was dose modifying but, at higher doses, the curves were parallel. When the MISO dose was reduced to 0.33 mg/g, the effect was reduced but not entirely lost. Only a small enhancement of CY response in the KHT tumour was seen with single doses, but the enhancement was greater with fractionated doses. The growth delay produced by CY in both tumour systems was reduced if WR 2721 (400 mg/kg) was given 30 min earlier. At a CY dose of 75-100 mg/kg the dose-modifying factor (DMF) was 0-7-0-8 but, at least in the RIF-1 tumour, was not so low at higher doses of CY.
consistent change in the pattern of body-weight loss after CY, but WR 2721 reduced the myelosuppression seen at 3-4 days after CY.
The data suggest that modification of tumour response to CY by the addition of MISO varies from tumour to tumour, and is very dependent upon the MISO dose. The protective effect of WR 2721 when combined with CY Is not confined to normal tissues, and at a dose of 400 mg/kg may be as great in terms of tumour response as in terms of acute LD50 in this system. At a lower dose of WR 2721, however, some differential protection may occur.
MUCH ATTENTION has been paid by radiobiologists to the problem of killing hypoxic, radio-resistant cells in solid tumours without producing unacceptable damage to the surrounding normal tissues. Two quite separate approaches have been found experimentally successful and are currently undergoing clinical trial. The first of these is the use of substances which selectively radiosensitize hypoxic cells whilst not changing the response of welloxygenated cells (e.g. misonidazole, MISO) (Adams, 1977) . The second approach has been to use sulphydryl radio-protective agents which are selectively excluded from tumour tissue (e.g. WR 2721) (Yuhas, 1980a) .
Recent studies have shown that these 51 two agents can, in addition to their interaction with ionizing radiation, also modify the response to various cytotoxic drugs. The hypoxic cells in solid tumours may well represent a population resistant to chemotherapy because of their distance from the blood supply, low rate of proliferation or hypoxia per se. MISO has been shown to be selectively cytotoxic to hypoxic cells both in vitro and in vivo (Hall & Roizin-Towle, 1975; Brown, 1977) , and may therefore be effective against those cells which survive conventional drug treatment. It has also been demonstrated that hypoxic pretreatment with MISO in vitro can sensitize cells to nitrogen mustard, melphalan and cis-platinum (Stratford et al., 1980) . A clear enhance-ment of cell kill in the Lewis lung tumour by the addition of MISO to cyclophosphamide (CY) and melphalan has been reported by Rose et al. (1980) , whilst Clement et al. (1980) have shown a variable enhancement of the anti-tumour activity of alkylating agents by MISO over a range of mouse tumours.
A series of studies by Yuhas and his co-workers has shown that WR 2721 is able to protect mice from the toxic effect of nitrogen mustard (Yuhas, 1979) and CY (Yuhas, 1980b) , and rats from cisplatinum-induced kidney damage (Yuhas & Culo, 1980) . In both of these studies, the alteration in tumour response to the chemotherapy was minimal. Differential protection by WR 2721 of normal mouse marrow cells as compared with the EMT6 tumour, has also been shown for a number of different cytotoxic drugs (Wasserman et al., 1981) .
In this paper, experiments are described in which CY treatment has been combined with either MISO or WR 2721. Growth delay in two different sarcomas of the C3H mouse has been used as a measure of tumour response. Loss of body weight, change in white-cell count and lethality have been stuidied as indicators of host response.
MATERIALS AND METHODS
Mice and tuanours.-The mice used in these studies wiere inbred C3H/He supplied by OLAC. Females wNere used in most experiments, but males w-ere used occasionally.
Mice entered experiments at age [12] [13] [14] [15] [16] wAeeks and weighed 20-28 g.
Tumours used were the KHT and RIF-1 sarcomas, both of wAhich originated in C3H/ Km mice at Stanford University, California, and w,hich have been previously described (Kallman et al., 1967; Twentyman et al., 1980) . The methods used for tumour cell inoculation into the gastrocnemius muscle of the hind limb and subsequent measurement of tumour growNth, including conversion of leg measurement to tumour weight, have also been described (Twentyman et al., 1979) . The endpoint of growth delay was calculated from the time taken for individual tumours to reach 4 x the initial group-mean treatment volume. Tumours were treated in the size ran-ge 300-600 mm3.
Nine to 12 mice were used in each treatment group. Table IV . In Experiment A, no significant increase in growth delay was brought about by the addition of MISO. In Experiment B, small but significant increases were seen. Two experiments in which lower doses of MISO were used are shown in Fig. 3 . The increase in growth delay caused by the addition of MISO is again seen to be similar at all doses of CY, indicating a loss of initial shoulder rather than change in the subsequent slope of the curve.
A multiple-dose experiment similar to that for the RIF-1 tumour was also done for KHT. The results are shown in Table   V . Growth delays of 3-3 and 15'1 days for CY alone were increased to 8-9 days and 23-0 days respectively with the addition of MISO. If the growth delay vs dose curve is linear in this region, these 11-3+0 4 9-9+0*7 10*1+0*9 10-6+0-8 400 0-8+0-4 11-3+0-4 8 5+1-4 7-7+0-5 8 8+0 7 All values are mean growth delay for 9-12 mice + s.e.
KHT.-The effect of combining WR 2721 with CY in the KHT tumour is shown in Table VII . The reduction in growth delay due to the lower dose of WR 2721 is of marginal significance in each case. At the higher dose, however, a highly significant reduction of 3-4 days is seen from the value of 12 days obtained by adding the delays due to CY and WR 2721 alone. There does not appear to be any great dependence of this effect on the relative times of administration of the two agents. On the basis of the previously determined shape of the CY response curve for this tumour (e.g. Fig. 3 is not seen, but apart from this, there is no apparent steepening of the curve with increasing CY dose. For WR 2721 pretreatment, the results shown in Fig. 7, panel (a) are difficult to interpret, because of the almost doubling of the count between Days 0 and 4 for mice receiving WR 2721 alone. There certainly appears to be no protection at 33 mg/kg of CY, but there is an apparently significant protection at the higher doses. All or part of this, however, may be related to the effect of WR 2721 alone in raising the Day 4 count. In the second experiment, where there was no count elevation by WR 2721, there is only a significant protection at 67 mg/kg of CY. Taken together, these 2 experiments, together with an additional experiment (not shown), indicate a tendency for WR 2721 to protect against CY depression of the whitecell count. It is not possible, however, to calculate a DMF for the effect, because of the complex shape of the curves.
DISCUSSION
Whereas MISO at a dose of 1 mg/g clearly increases the growth delay due to CY in the RIF-1 tumour, this is not true in KHT (though it should be noted that enhancement is seen in KHT using lower, fractionated doses). This is the opposite of what would, perhaps, have been expected if enhancement depended on the presence within the tumour of a considerable proportion of radiobiologically hypoxic cells. The RIF-1 tumour growing intramuscularly has essentially no cells which are fully hypoxic, and when growing in the flank has a hypoxic fraction of only 2% whereas KHT in the flank has a hypoxic fraction of 14% 752 0 (van Putten & Kallman, 1968) . (There are no data available for KHT growing intra-muscularly.)
The shape of the curve for MISO + CY in RIF-1 (Fig. 1) also argues against the effect being due to sensitization of a relatively CY-resistant fraction of cells, because the major enhancement occurs at low CY doses. Such an effect would rather reflect either a specific sensitization of a relatively CY-sensitive subpopulation, or a lethal interaction between sub-lethal damage caused by the two individual agents.
In both tumour systems, there is only a small enhancement of CY response by 0 33 mg/g of MISO, and, in terms of blood levels which can be achieved in the clinic, this is still a very high dose. (The longer half-life of MISO in man may, however, contribute to enhancement despite lower peak levels.) In a study very similar to that reported here, Law et al.
(submitted) have also found an enhancement of CY growth delay in the RIF-1 tumour by 0 75 mg/g of MISO. They also, however, found that a dose enhancement of about 2 in the early part of the curves gave way to parallel curves above a CY dose of about 50 mg/kg. In Tannock's (1980) Rose et al. (1980) did not present normal tissue data for CY, but for another alkylating agent (melphalan) they showed that the dose enhancement seen against marrow stem cells was less than that for the Lewis lung tumour. Tannock (1980) on the other hand, using weight loss and depression of white-cell count as endpoints of normal tissue toxicity, concluded that addition of MISO to CY was therapeutically disadvantageous in his studies. The combination appeared to be advantageous for treatment of the M5076 ovarian carcinoma, but disadvantageous in the B16 melanoma (Clement et al., 1980) .
In their studies comparing RIF-1 tumour response with marrow stem-cell response, Law et al. (submitted) show an improved therapeutic index for CY doses below 100 mg/kg, but above this dose the picture is less certain. Our studies reported here seem to support the less encouraging view of the likely usefulness of the combination. It is true that MISO (1 mg/g) does not appear to systematically increase CY-induced weight loss, nor does it greatly increase depression of white-cell count by CY. There may well, therefore, be a therapeutic gain at low (and clinically relevant) doses of CY in the RIF-1 tumour, where the dose enhancement is 2. In the KHT tumour, however, the enhancement at 1 mg/g of MISO is much less than in RIF-1, and at a MISO dose of 0 33 mg/g the enhancement in RIF-1 is considerably reduced. This reduced MISO dose does, however, cause a small but repeatable decrease in the LD50 of CY, and may not, therefore, be therapeutically advantageous.
At the moment, there is no clear indication of the mechanism whereby MISO enhances tumour response to CY. As mentioned earlier in this discussion, several aspects of the data would argue against it being directly related to enhanced killing of hypoxic cells. One thing that is clearly established is that high doses of MISO cause a severe and prolonged reduction in body temperature in mice (G-omer & Johnson, 1979) . It would appear likely that this could cause profound alterations in CY metabolism, which would involve enzyme action. However, it is difficult to see how this could result in improvement in therapeutic ratio, as has been reported in some of the studies detailed above. Furthermore, it has been shown that enhancement of tumour response to CY can be caused by another radiosensitizer (SR 2508) which does not cause a drop in body temperature (Law et al., submitted). There is evidence also that MISO may inhibit the recovery from CY-induced potentially lethal damage in the RIF-1 tumour (Law et al., submitted) but this may itself be related to possible pharmacokinetic alterations.
Our studies with WR 2721 show that the relative protection of normal tissue compared with tumour response in our system is less than might have been expected from other data in the literature. Although 200 mg/kg has only a small effect on the CY response of either tumour, the higher dose of 400 mg/kg produces a IDMF for tumour response of 0 5-0-8, depending upon CY dose. This compares with a mean value of 0-8 for lethality. In his studies on nitrogen-mustard lethality, Yuhas (1979) found a DMF of 0 5 for 350 mg/kg of WR 2721, and, in rats, Yuhas & Culo (1980) found a DMF of -0'6 for kidney damage if WR 2721 (200 mg/kg) were given before cisplatinum. More recently, Yuhas (1980b) reported a DMF of 0 7 for CY lethality in mice pretreated with 200 mg/kg of WR 2721. Using marrow CFUs as an endpoint, Wasserman et al. (1981) found a DMF of -0-4 for WR 2721 (600 mg/kg) injected before CY. In this latter study, the growth delay in the EMT6 tumour due to CY was reduced from 12 to 10 days by pretreatment with WR 2721, whereas in the other 3 studies (Yuhas, 1979; Yuhas, 1 980b; Yuhas & Culo, 1980) Yuhas (1979) found DMFs of 0-65, 0 50 and 0-65 at 200, 400 and 500 mg/kg of WR 2721 respectively. The reduced protection at the highest dose was ascribed to an artefact of a direct toxic interaction between the two agents, rather than a failure of protection per se. One reason given for this was that deaths in this group occurred much earlier than those in groups receiving HN2 alone, or HN2 plus low doses of WR 2721. In our studies, however, no such unusually early deaths were seen, and hence it appears unlikely that we are seeing a similar toxic interaction when combining 400 mg/kg of WR 2721 with CY. The DMF for lethality in the one experiment with 200 mg/kg of WR 2721 was, however, similar to that at 400 mg/kg, though the tumour protection is much less at this dose (Table VII) . This would suggest that optimal relative protection may be seen for reduced WR 2721 dose. Our results suggest that the differential protection against CY produced by WR 2721 may be considerably less than that reported for radiation (Yuhas, 1980a) or for nitrogen mustard (Yuhas, 1979) . A differential protection may be seen at relatively low doses of WVR 2721 but this is lost with increasing dose.
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